Abstract
We read with interest the work of Miki Takemura and colleagues who observed global patterns of cefiderocol resistance amongst isolates producing MBLs collected in North America and Europe in multinational SIDERO-WT surveillance studies.1 The SIDERO-WT surveillance studies conducted between 2014 and 2019 included approximately 46 000 Gram-negative clinical isolates. It was found that 200/902 (22.0%) of meropenem-resistant Enterobacterales isolates produced MBL enzymes, 67.5% of which had a cefiderocol MIC value of less than the 2 mg/L breakpoint set by EUCAST. Carbapenemase-producing Gram-negative bacteria pose a significant threat to health as there are limited therapeutic options,2 especially for isolates that produce MBL enzymes. However, cefiderocol may retain activity against Enterobacterales that produce MBL enzymes. The gold standard method for antimicrobial susceptibility testing (AST) of cefiderocol is broth microdilution (BMD) using iron-depleted cation-adjusted Mueller–Hinton broth,3 but this is not readily in available in most clinical laboratories. Disc diffusion (DD) is relatively easier, lower in cost and a well-standardized method for AST in clinical laboratories and, for cefiderocol, does not require iron-depleted media. Interpretive criteria and breakpoints for BMD and DD have been defined by EUCAST. However, breakpoints for DD have required adjustment, with the latest guidance update as of 1 January 2024 showing a change from 22 mm [area of technical uncertainty (ATU) 18–22 mm] to 23 mm (ATU 21–23 mm) for Enterobacterales. The MIC breakpoints have remained the same in the latest edition.4